ARKO Corp. (ARKO): Nasdaq/NYSE listing notice — ARKO non-compliant with Nasdaq audit committee rule after director resignation; cure period until Nov 1, 2023

ARKO Corp.

Director Starlette Johnson resigned from board and audit committee effective May 5, 2023.
Audit Committee now has fewer than three members, violating Nasdaq Listing Rule 5605(c)(2).
Nasdaq confirmed non-compliance on June 2, 2023; cure period expires November 1, 2023.
Company expects to cure before deadline and actively seeking audit committee replacement.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ARKO Corp. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)(B)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605(c)(2), 5605(c)(4)(B)

Exact text from the filing

June 2, 2023, the Company received a notification from Nasdaq confirming the foregoing and that, as permitted by Nasdaq Listing Rule 5605(c)(4)(B), the Company has until November 1, 2023 to cure this non-compliance. The Company expects to cure this non-compliance prior to November 1, 2023 and has an active search underway to fill the vacancy on the Audit Committee. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARKO Corp. Date: June 2, 2023 By: /s/

View on SEC.gov

Browse all listing & compliance notices →

ARKO Corp. filing history →

Source: SEC EDGAR

accession 0000950170-23-026140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.